六君子汤加减对老年中晚期肺癌化疗患者免疫功能的保护作用

Protective Effect of Modified Liujunzi Tang on Immunity in Elderly Patients with Advanced Lung Cancer Undergoing Chemotherapy

目的:观察六君子汤加减对老年中晚期肺癌化疗患者免疫功能的保护作用。方法:选择老年中晚期肺癌患者80例,按照随机数字表法分为观察组和对照组,每组40例。对照组采用含铂两药化疗方案治疗,观察组在对照组治疗基础上服用六君子汤加减治疗,21天为1个周期,共治疗2个周期。检测两组患者治疗前后免疫功能指标:T淋巴细胞亚群CD3^(+)、CD4^(+)、CD8^(+),免疫球蛋白M(immunoglobulin M,IgM),免疫球蛋白G(immunoglobulin G,IgG),免疫球蛋白A(immunoglobulin A,IgA)水平;肿瘤标志物:细胞角蛋白十九片段(CYFRA21-1)、血清糖类抗原125(carbohydrate antigen 125,CA-125)、神经元特异性烯醇化酶(neuron specific enolase,NSE)、癌胚抗原(carcinoembryonic antigen,CEA)水平;采用肺癌患者生活质量测定量表(functional assessment of cancer therapy-lung,FACT-L)评价患者生活质量;统计疾病控制率和不良反应发生率。结果:治疗后,观察组CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)、IgA、IgG、IgM水平高于对照组(P<0.05),CD8^(+)水平、CEA、AFG、CA125、NSE水平低于对照组(P<0.05)。观察组FACT-L评分高于对照组(P<0.05)。观察组疾病控制率[95.00%(38/40)]高于对照组[85.00%(34/40)](P<0.05)。观察组不良反应发生率[5.56%(3/54)]低于对照组[18.52%(10/54)](P<0.05)。结论:六君子汤加减治疗老年中晚期肺癌化疗患者,可保护患者免疫功能,降低肿瘤标志物水平,提升患者生活质量,疾病控制率,降低患者不良反应发生率。

Objective:To observe protective effects of modified Liujunzi Tang on immunologic function in senile patients with advanced lung cancer undergoing chemotherapy.Methods:Eighty patients were chosen,and divided into the observation group and the control group according to random number table method,with 40 cases in each group.The control group was treated with platinum-containing two-drug chemotherapy regimen,and the observation group took modified Liujunzi Tang based on chemotherapy regimen,21 days were one cycle,both groups were treated for two cycles.To detect the indexes of immunologic function before and after treatment within two groups:the levels of T lymphocyte subsets CD3^(+),CD4^(+)and CD8^(+),IgM,IgG and IgA;and tumor markers:the levels of CYFRA21-1,CA-125,NSE and CEA;FACT-L was adopted to assess quality of life;to count disease control rate and the incidence of adverse reaction.Results:After the treatment,the observation group was higher than the control group in the levels of CD3^(+),CD4^(+),CD4^(+)/CD8^(+),IgA,IgG and IgM(P<0.05),lower than the control group in the levels of CD8^(+),CEA,AFG,CA125 and NSE(P<0.05).FACT-L scores of the observation group were higher than these of the control group(P<0.05).Disease control rate of the observation group was[95.00%(38/40)],higher than[85.00%(34/40)]of the control group(P<0.05).The incidence of adverse reaction of the observation group was[5.56%(3/54)],lower than[18.52%(10/54)]of the control group(P<0.05).Conclusion:Modified Liujunzi Tang in treating senile patients with advanced lung cancer undergoing chemotherapy could protect immunologic function,lower the levels of tumor markers,raise quality of life,disease control rate and reduce the incidence of adverse reaction.